A phase III study of coversin in naive patients with paroxysmal nocturnal hemoglobinuria.
Phase of Trial: Phase III
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Coversin (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Therapeutic Use
- Acronyms CAPSTONE
- 21 Sep 2017 According to an Akari Therapeutics media release, following advice from a recent FDA Type B End of Phase II Meeting, company plans to initiate this trial in Q1 2018.
- 24 Apr 2017 According to Akari Therapeutics media release, the company is planning to initiate this phase III program in the fourth quarter of 2017 andanticipates initial data in first quarte of 2019.
- 27 Jan 2017 New trial record